Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes
2019-000781-38Phase 4Completed
- Sponsor
- Aarhus University Hospital
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin arm with Semaglutide arm (2 arms). Primary endpoints: Change in arterial stiffness and Change in renal oxygenation. Started Mar 2019; status: completed.
02
Drugs
empagliflozinsemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-000781-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000781-38.